Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot
02:11pm, Thursday, 19'th Dec 2024
The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
01:06pm, Thursday, 19'th Dec 2024
On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower ba
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years
11:23am, Thursday, 19'th Dec 2024
Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study.
Block & Leviton is investigating Vertex Pharmaceuticals (Nasdaq: VRTX) for potential securities fraud. Investors who lost money should contact the firm.
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
10:31am, Thursday, 19'th Dec 2024
Vertex Pharmaceuticals (VRTX) shares sank Thursday morning after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
Cramer's Stop Trading: Vertex Pharmaceuticals
10:17am, Thursday, 19'th Dec 2024
CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
07:09am, Thursday, 19'th Dec 2024
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
06:00am, Thursday, 19'th Dec 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal
2 Unstoppable Stocks to Buy and Hold for the Next Decade
04:20am, Thursday, 19'th Dec 2024
What do Apple (AAPL -2.14%) and Vertex Pharmaceuticals (VRTX -4.63%) have in common? At first glance, not much.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Wednesday, 18'th Dec 2024
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
4 Big Drug Stocks That May Continue to Outperform in 2025
11:06am, Tuesday, 17'th Dec 2024
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today
06:51pm, Monday, 16'th Dec 2024
Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.
BMY vs. VRTX: Which Stock Is the Better Value Option?
12:45pm, Monday, 16'th Dec 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
04:15am, Monday, 16'th Dec 2024
Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these c
3 Unstoppable Stocks to Buy Right Now
06:07am, Sunday, 15'th Dec 2024
Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals.
